URGN
UroGen Pharma Ltd.
NASDAQ · Healthcare · Biotechnology · US
$44.09
−1.76%Forward multiples
Based on analyst estimates
- P/E forward
- 35.83x
- P/E 2026E
- —
- P/E 2027E
- 17.34x
- P/E 2028E
- 8.78x
- P/S forward
- 4.89x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- -16.28x
- Price / sales
- 11.42x
- Price / cash flow
- -13.56x
Enterprise value
- Enterprise value
- $2.2B
- EV / sales
- 11.89x
- EV / EBITDA
- -31.72x
- EV / EBIT
- -33.66x
- Market cap
- $2.2B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026